Clinical Trials
17 trialsNCT00445341 2018-01-30
Flavopiridol to Treat Relapsed Mantle Cell Lymphoma or Diffuse Large B-Cell Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT00058240 2017-07-02
Flavopiridol in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00098371 2016-10-24
Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00112723 2016-08-08
Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
National Cancer Institute (NCI)
Phase 1/2 Terminated
NCT01076556 2015-11-11
Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00019344 2015-04-29
Flavopiridol in Treating Patients With Refractory Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00735930 2015-04-02
Lenalidomide and Alvocidib in Treating Patients With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00082784 2014-12-23
Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms
National Cancer Institute (NCI)
Phase 1 Completed
NCT00016016 2013-10-08
Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Acute Leukemia
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00470197 2013-09-30
Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Relapsed or Refractory Acute Leukemia
National Cancer Institute (NCI)
Phase 1 Completed
NCT00012181 2013-07-02
Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas
National Cancer Institute (NCI)
Phase 1 Completed
NCT00377104 2013-07-02
Alvocidib in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00058227 2013-06-04
Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00101231 2013-06-04
Flavopiridol in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00278330 2013-04-02
Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory Anemia
National Cancer Institute (NCI)
Phase 1 Completed
NCT00003039 2013-02-05
Flavopiridol in Treating Patients With Recurrent Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00003620 2013-01-17
Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 2 Completed